Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in B-cell malignancies with COVID-19
NCT04665115Phase 2Withdrawn
- Sponsor
- Academic and Community Cancer Research United
- Start
- Nov 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in coronavirus disease 2019 (COVID-19), sponsored by Academic and Community Cancer Research United. Planned start Nov 2020; status: withdrawn.
02
Drugs
ibrutinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04665115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665115.